{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:11:50Z","timestamp":1791893510340,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.4158\/ep14430.ra","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T22:32:00Z","timestamp":1415226720000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S1","title":["Acromegaly: Assessing the Disorder and Navigating the Therapeutic Options for Treatment"],"prefix":"10.1016","volume":"20","author":[{"given":"Shlomo","family":"Melmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kleinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Bonert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP14430.RA_bb0005","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest."},{"key":"10.4158\/EP14430.RA_bb0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrendo.2011.40","article-title":"Pathogenesis of pituitary tumors","volume":"7","author":"Melmed","year":"2011","journal-title":"Nat Rev Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0079-6123(10)82009-6","article-title":"Pathogenesis of pituitary tumors","volume":"182","author":"Yu","year":"2010","journal-title":"Prog Brain Res."},{"key":"10.4158\/EP14430.RA_bb0020","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Eng J Med."},{"key":"10.4158\/EP14430.RA_bb0025","unstructured":"Korbonits M, Kumar AV. AIP-related familial isolated pituitary adenomas. GeneReviews\u00ae. NCBI Bookshelf. Available at: http:\/\/www. ncbi.nlm.nih.gov\/books\/NBK97965\/. Accessed June 18, 2014."},{"key":"10.4158\/EP14430.RA_bb0030","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1210\/jc.2005-2671","article-title":"Clinical characterization of familial isolated pituitary adenomas","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/er.2012-1013","article-title":"Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (IP) gene","volume":"34","author":"Beckers","year":"2013","journal-title":"Endocr Rev."},{"key":"10.4158\/EP14430.RA_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1008020","article-title":"AIP mutation in pituitary adenomas in the 18th century and today","volume":"364","author":"Chahal","year":"2011","journal-title":"N Eng J Med."},{"key":"10.4158\/EP14430.RA_bb0045","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2012-1274","article-title":"Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome","volume":"97","author":"Vortmeyer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0050","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2265.2003.01734.x","article-title":"Primary medical therapy for acromegaly","volume":"58","author":"Sheppard","year":"2003","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP14430.RA_bb0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u2018cure\u2019","volume":"152","author":"Nomikos","year":"2005","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0070","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0075","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP14430.RA_bb0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Signifcant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"suppl 1","key":"10.4158\/EP14430.RA_bb0085","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","article-title":"ACROSTUDY: the first 5 years","volume":"161","author":"Trainer","year":"2009","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0090","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0095","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Eng J Med."},{"key":"10.4158\/EP14430.RA_bb0100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jc.2005-1616","article-title":"Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly","volume":"91","author":"Jenkins","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.17925\/EE.2009.05.00.51","article-title":"Advances in our understanding of acromegaly--is there an optimal treatment regimen?","volume":"5","author":"Higham","year":"2009","journal-title":"US Endocrinology Touch Briefings."},{"issue":"3","key":"10.4158\/EP14430.RA_bb0110","doi-asserted-by":"crossref","first-page":"R223","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin receptor ligands and resistance to treatment in pituitary adenomas","volume":"52","author":"Cuveas-Ramos","year":"2014","journal-title":"J Mol Endocrinol."},{"issue":"suppl 4","key":"10.4158\/EP14430.RA_bb0115","first-page":"1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly \u2013 2011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract."},{"key":"10.4158\/EP14430.RA_bb0120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2265.2007.03044.x","article-title":"Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective","volume":"68","author":"Bevan","year":"2008","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP14430.RA_bb0125","doi-asserted-by":"crossref","DOI":"10.3171\/2010.7.FOCUS10154","article-title":"Acromegaly: a review of current medical therapy and new drugs on the horizon","volume":"29","author":"Fleseriu","year":"2010","journal-title":"Neurosurg Focus."},{"key":"10.4158\/EP14430.RA_bb0130","series-title":"SANDOSTATIN LAR [Package insert]","year":"2014"},{"key":"10.4158\/EP14430.RA_bb0135","series-title":"SOMATULIN DEPOT [Package insert]","year":"2012"},{"key":"10.4158\/EP14430.RA_bb0140","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061523","article-title":"Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis","volume":"8","author":"Pita-Gutierrez","year":"2013","journal-title":"PloS One."},{"key":"10.4158\/EP14430.RA_bb0150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","article-title":"Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review","volume":"14","author":"Fleseriu","year":"2011","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0155","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-07-0383","article-title":"Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly","volume":"157","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PloS One."},{"key":"10.4158\/EP14430.RA_bb0170","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0175","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/2010.7.FOCUS10169","article-title":"Growth hormone-secreting adenomas: pathology and cell biology","volume":"29","author":"Lopes","year":"2010","journal-title":"Neurosurg Focus."},{"key":"10.4158\/EP14430.RA_bb0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00418-008-0472-1","article-title":"Pathology of the human pituitary adenomas","volume":"130","author":"Osamura","year":"2008","journal-title":"Histochem Cell Biol."},{"key":"10.4158\/EP14430.RA_bb0185","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0190","series-title":"SOMAVERT [Package insert]","year":"2012"},{"key":"10.4158\/EP14430.RA_bb0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-10-0867","article-title":"Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone","volume":"164","author":"van der Lely","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0200","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0205","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina","year":"2009","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0225","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0230","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","article-title":"Clinical, quality of life, and economic value of acromegaly disease control","volume":"14","author":"Ben-Shlomo","year":"2011","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0235","doi-asserted-by":"crossref","first-page":"268957","DOI":"10.1155\/2012\/268957","article-title":"Medical therapy of acromegaly","volume":"2012","author":"Plockinger","year":"2012","journal-title":"Int J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0240","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0245","unstructured":"Fleseriu M. Acromegaly: update on somatostatin receptor ligands. 2012. Available at: http:\/\/www.medscape.org\/ viewarticle\/767865_transcript. Accessed June 19, 2014."},{"key":"10.4158\/EP14430.RA_bb0250","article-title":"Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study. Presented at the Society for Endocrinology ICE\/ECE, Florence, Italy","author":"Fleseriu","year":"2012","journal-title":"Endocrine Abstracts."},{"key":"10.4158\/EP14430.RA_bb0255","unstructured":"Chiasma. TPE(TM) System. 2014. Available at: http:\/\/www.chiasmapharma.com\/page. asp?id=27. Accessed June 19, 2014."},{"key":"10.4158\/EP14430.RA_bb0260","series-title":"Efficacy and safety of oral octreotide in acromegaly: results of a multicenter phase III trial in 155 patients","first-page":"OR17","author":"Melmed","year":"2014"},{"key":"10.4158\/EP14430.RA_bb0265","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0270","unstructured":"Camurus. CAM2029 growth hormone disorders. 2014; Available at: http:\/\/www.camurus.com\/index.asp?DocumentID=2&DocumentIDSub=3&Lang=&ShowSub=(2)&Show= (2)&main=Products. Accessed June 23, 2014."},{"key":"10.4158\/EP14430.RA_bb0275","first-page":"P914","article-title":"Octreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, phase I, repeat-dose study in healthy volunteers","volume":"35","author":"Roberts","year":"2014","journal-title":"Endocrine Abstracts."},{"key":"10.4158\/EP14430.RA_bb0280","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0285","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","article-title":"Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations","volume":"17","author":"Colao","year":"2014","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0290","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1227\/NEU.0b013e31823f5c16","article-title":"Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly","volume":"70","author":"Kim","year":"2012","journal-title":"Neurosurgery."},{"key":"10.4158\/EP14430.RA_bb0295","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","article-title":"Predictors and rates of treatment-resistant tumor growth in acromegaly","volume":"153","author":"Besser","year":"2005","journal-title":"Eur J Endocrinol."},{"key":"10.4158\/EP14430.RA_bb0300","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1590\/S0004-27302011000700011","article-title":"Postglucose growth hormone nadir and insulin-like growth factor-1 in na\u00efve-active acromegalic patients: do these parameters always correlate?","volume":"55","author":"Ribeiro-Oliveira","year":"2011","journal-title":"Arq Gras Endocrinol Metab."},{"key":"10.4158\/EP14430.RA_bb0305","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11102-011-0369-1","article-title":"Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly na\u00efve to medical therapy and radiation: what to follow, GH or IGF-1 values?","volume":"15","author":"Brzana","year":"2012","journal-title":"Pituitary."},{"key":"10.4158\/EP14430.RA_bb0310","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20429477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20429477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/C03L2027HW21P3N5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:55:46Z","timestamp":1761515746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20429477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":62,"alternative-id":["S1530891X20429477"],"URL":"https:\/\/doi.org\/10.4158\/ep14430.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acromegaly: Assessing the Disorder and Navigating the Therapeutic Options for Treatment","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP14430.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}